Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $42.4 million.

  • Standard Biotools' Operating Expenses rose 926.46% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.0 million, marking a year-over-year increase of 2893.34%. This contributed to the annual value of $259.5 million for FY2024, which is 10424.87% up from last year.
  • As of Q3 2025, Standard Biotools' Operating Expenses stood at $42.4 million, which was up 926.46% from $36.3 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Operating Expenses registered a high of $124.6 million during Q4 2024, and its lowest value of $28.9 million during Q1 2023.
  • Over the past 5 years, Standard Biotools' median Operating Expenses value was $42.4 million (recorded in 2025), while the average stood at $48.0 million.
  • In the last 5 years, Standard Biotools' Operating Expenses crashed by 4653.66% in 2023 and then skyrocketed by 25854.42% in 2024.
  • Standard Biotools' Operating Expenses (Quarter) stood at $49.5 million in 2021, then tumbled by 34.82% to $32.3 million in 2022, then rose by 7.63% to $34.7 million in 2023, then soared by 258.54% to $124.6 million in 2024, then tumbled by 65.94% to $42.4 million in 2025.
  • Its Operating Expenses stands at $42.4 million for Q3 2025, versus $36.3 million for Q2 2025 and $52.7 million for Q1 2025.